Leqembi and the Alzheimer’s Impasse: Hope, Cost, and Caution in France
Table of Contents
A new Alzheimer’s treatment, Leqembi, offers a glimmer of hope to families affected by the devastating disease, but access remains limited, particularly in France, where health authorities have rejected a fast-track reimbursement request. Developed by Biogen and Eisai, Leqembi targets amyloid plaques in the brain – a long-studied approach – and represents one of the first drugs to demonstrate even a modest slowing of cognitive decline. However, concerns over cost, side effects, and the drug’s overall clinical significance are fueling a complex debate.
France Denies Early Access to Leqembi
On September 9, 2025, France’s High Health Authority (HAS) delivered a decisive blow to hopes for rapid access to Leqembi, denying its inclusion in an “early access” program. This would have allowed for immediate coverage by the national healthcare system, even for patients lacking alternative treatment options. According to a senior official at the HAS, the decision stemmed from “profits that are very insufficient compared to what we expected” and “side effects which are not weak at all.”
The early access system is reserved for truly innovative therapies, but the HAS concluded that Leqembi’s benefit-risk profile did not warrant such an exception. This decision underscores the stringent requirements for new drug approval in France and the emphasis on value for money within the public healthcare system.
Modest Benefits and Significant Risks
Proponents of Leqembi emphasize its potential to buy patients precious time – a few extra months of lucidity, of meaningful interaction with loved ones. This resonates deeply with those who have witnessed the relentless erosion of memory caused by Alzheimer’s. However, clinical trial data reveals a more nuanced picture. While the drug demonstrated a statistically significant slowing of cognitive decline, the clinical significance of this effect remains hotly debated.
Adding to the concerns are potentially serious side effects, including brain hemorrhages and edema, some of which have proven fatal. The European Medicines Agency has responded cautiously, restricting Leqembi’s use to patients at the lowest risk of these adverse events.
“A few months of lucidity gained, that counts,” noted a neurologist at Pitié-Salpêtrière hospital, expressing disappointment with the French decision. Conversely, a psychiatrist at University College London welcomed the caution, stating, “These treatments do not really modify the disease.”
The High Cost of Hope
The financial burden of Leqembi is substantial. In the United States, the annual cost exceeds $26,000, placing it beyond the reach of many families. This high price tag raises serious questions about the sustainability of such treatments for healthcare systems globally.
The United Kingdom has already opted not to reimburse Leqembi, despite its marketing authorization, citing cost concerns. In France, the HAS has warned that a “fantastic evaluation” during the traditional reimbursement process is unlikely. Official authorization is expected in the European Union in spring 2025, but this does not guarantee financial support from individual member states.
A Growing Frustration and a Call for Diversification
Patient associations are grappling with a mix of frustration and determination. For many, Leqembi represents the first tangible breakthrough in decades, a beacon of hope after years of failed clinical trials. However, the controversy persists: is it a genuine advance or a costly mirage?
A growing criticism centers on the decades-long focus on the amyloid trail in Alzheimer’s research. Many argue that the field needs to diversify its strategies and invest in alternative approaches. The urgency of this call is increasingly evident in public debate.
Global Access to Leqembi: A Snapshot
Here’s a look at the regulatory status and reimbursement landscape for Leqembi around the world:
| Country | Regulatory Status | Reimbursement |
|---|---|---|
| UNITED STATES | FDA Approval | Reimbursed according to insurance contracts |
| European Union | Approval with restrictions (spring 2025) | At the discretion of Member States |
| Japan | Commercialization effective | Partial refund |
| United Kingdom | Allowed | Not refunded |
| Suisse | Evaluation in progress | Non applicable |
FAQ: Understanding the Leqembi Debate
Why is France blocking reimbursement?
The HAS believes that the benefits provided by Leqembi do not outweigh the risk of serious side effects and that the medical benefit does not justify accelerated treatment or the high cost.
Will Leqembi one day be reimbursed in France?
The possibility remains open. The drug will undergo a standard evaluation process, but the HAS has expressed low expectations. Reimbursement will depend on new data or a change in the benefit-risk ratio.
Are there any alternatives?
Currently, no revolutionary alternatives exist. Symptomatic treatments – such as anticholinesterases and memantine – remain the standard of care. Emerging avenues, excluding the amyloid approach, include the Mind diet, blood biomarkers, and cognitive stimulation, but no miracle solution has yet been discovered.
How much does the treatment cost?
Leqembi costs over $26,000 per year in the United States. Without reimbursement, the cost is prohibitive for most families in France.
Alzheimer’s disease continues to disrupt the lives of tens of millions worldwide. Every month of preserved memory and every moment of connection holds immeasurable value for families. The debate surrounding Leqembi highlights a critical impasse: an undeniable scientific advance, yet a clinical revolution that is slow to materialize. Between promise and caution, the fight against Alzheimer’s is still seeking its breakthrough.
